XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Payments (Tables)
 6 Months Ended
Oct. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of allocation of share based compensation expense
Stock-based compensation expense was recognized as follows (table in thousands):
 
Three Months Ended
October 31,		Six Months Ended
October 31,
 2023202220232022
General and administrative$31 $23 $215 $146 
Sales and marketing21 49 87 97 
Research and development1 4 12 7 
Cost of oncology services— 43 162 75 
Total stock-based compensation expense$53 $119 $476 $325 
Summary of valuation assumptions for stock options Black-Scholes assumptions used to calculate the fair value of options granted during the three and six months ended October 31, 2023 and 2022 were as follows:
 
Three Months Ended
October 31,		Six Months Ended
October 31,
 2023202220232022
Expected term in years
6
6
6
6
Risk-free interest rates
4.49%
0.00%
3.95% - 4.49%
2.87%
Volatility
63.30%
0.00%
62.83% - 63.30%
62.58%
Dividend yield—%—%—%—%
Summary of stock option activity
The Company’s stock options activity for the six months ended October 31, 2023 was as follows:
 
Directors
and
Employees		Non-
Employees		TotalWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding, April 30, 20231,739,336 36,331 1,775,667 $4.80 4.6$2,683,000 
Granted279,100 — 279,100 6.40 9.9
Exercised(155,449)— (155,449)2.31 
Forfeited(32,000)— (32,000)5.86   
Canceled(34,618)— (34,618)3.98 
Expired(833)— (833)15.96   
Outstanding, October 31, 20231,795,536 36,331 1,831,867 5.25 4.6$2,685,000 
Vested and expected to vest as of October 31, 20231,795,536 36,331 1,831,867 5.25 4.6$2,685,000 
Exercisable as of October 31, 20231,478,204 1,875 1,480,079 4.91 4.0$2,675,000